Tara Biosystems publishes Biowire II heart-on-a-chip platform research

Charlotte Edwards 25 January 2019 (Last Updated January 25th, 2019 15:44)

Tara Biosystems, a company which creates human heart-on-a-chip tissue models for cardiac risk assessment and drug discovery uses, has announced the publication of its first peer-reviewed research paper regarding its Biowire II platform.

Tara Biosystems publishes Biowire II heart-on-a-chip platform research
In clinical trials, Barostim Neo was shown to improve patients’ quality of life, their exercise capacity, and functional status Credit: Wagner Souza e Silva / Museum of Veterinary Anatomy FMVZ USP.

Tara Biosystems, a company which creates human heart-on-a-chip tissue models for cardiac risk assessment and drug discovery uses, has announced the publication of its first peer-reviewed research paper regarding its Biowire II platform.

The principal author of the article was Tara Biosystems scientific co-founder Dr Milica Radisic who is also a professor of chemical engineering and applied chemistry at the University of Toronto.

The research has been published in the international journal Cell. It details how the Biowire II platform is able to create multiple human heart tissue types in vitro. It also states how the researchers were able to generate tissue models of human disease from cardiomyocytes derived from induced pluripotent cells of affected patients.

The research team believes that these engineered human tissues represent a major technological advancement in their quest to discover and develop safer, more effective therapies.

Tara CEO Dr Misti Ushio said: “The publication of Tara’s Biowire II platform in the prestigious journal Cell showcases the unprecedented innovation on which Tara was founded. The Cell paper validates the ability of the Biowire II platform to engineer physiologically relevant cardiac tissues in vitro and to generate human relevant cardiac data.

“Our Biowire II platform is the only solution in the market today that offers accurate prediction of cardiac function across three primary applications: integrated and high fidelity cardiac testing for rapid preclinical cardiac risk assessment, disease modelling for cardiac disease drug discovery, and conducting clinical trials in vitro.”

Radisic said: “The creation of complex cardiac models that accurately mimic the human heart has been a major challenge in our field. With the Biowire II platform, we are able to generate cardiac tissues that have tremendous potential for evaluating the safety and efficacy of new therapies and for predicting drug response.”

The research paper can be found in the online version of Cell and will appear in the 7 February 2019 issue of the journal.